Aspira Women's Health
Biotechnology ResearchView the employees at
Aspira Women's Health-
Tom Colella Purchasing Manager at Vermillion, Inc.
-
Wichita, Kansas, United States
-
Rising Star
Matt Ramey Business Development | Laboratory Diagnostics Expert-
Atlanta, Georgia, United States
-
Top 10%
Torsten Hombeck, Ph.D. CFO @ Aspira Women's Health | Biotech Entrepreneur | Capital Raises, M&A, Partnering-
New York
-
Top 5%
Susan Carruthers Executive Assistant to the Executive Chairperson.-
El Cajon, California, United States
-
Rising Star
Nicolette Possemato SVP of Human Resources-
Sandy Hook, Connecticut, United States
-
Rising Star
Overview
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.
-